Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Alps Dx has filed to raise $3.25M in a seed round for its oral fluid drug testing technology. The funding aims to enhance lab efficiency through automation and innovative processing workflows.
Alps Dx, a diagnostics tooling and automation startup based in Richmond, Virginia, has filed a notice with the SEC to raise up to $3.25M in a seed round. The company aims to improve the speed and safety of oral fluid drug testing workflows. Led by CEO Ali Safavi, Alps Dx focuses on enabling laboratories to adopt automation without significant capital investments. This funding reflects a modest investment in a young company poised to modernize diagnostics.
Company Information
Company
Alps Dx
Location
Richmond, Virginia, United States
About
Alps Dx develops automated and connected technologies that modernize oral fluid workflows across laboratories, workplaces, and emerging decentralized collection environments. The company's portfolio includes purpose-built instruments, consumables, workflow software, and applications designed to improve operation. Their products aim to enhance sample preparation efficiency and reduce error-prone manual processes in toxicology laboratories. With innovations like Xpressor and Atelier, Alps Dx supports laboratories in improving sample integrity and operational consistency.
Don't miss Alps Dx's next move
Get an email the moment Alps Dx raises, hires an exec, or expands, usually minutes after it happens.
RichmondManufacturingBiotechnologySoftwareMedical Device